Mannitol

Mannitol increases the osmolarity of plasma and glomerular filtrate after intravenous administration. The resulting osmotic gradient limits water and solute reabsorption in the renal tubules, producing a diuretic effect, while also pulling fluid from the brain and eye, thereby decreasing pressure in those compartments.

The dose of Mannitol is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal function, and desired therapeutic effect. No fixed regimen is provided here; dosing must follow the prescriber's order and institutional protocols.

Safety data for Mannitol during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Mannitol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mannitol is a widely used osmotic diuretic with rapid onset when given intravenously. Compared with agents such as hypertonic saline, Mannitol provides both diuretic and pressure‑lowering effects, but may carry a higher risk of electrolyte disturbances. Choice of agent depends on the clinical scenario and physician judgment.

Mannitol injection solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking the vial. Do not use if the solution appears discolored or contains particles.

Mannitol is administered intravenously, typically as a sterile injection solution. It may be given as a slow infusion or bolus, depending on the indication and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting where vital signs and fluid balance can be monitored.

Serious risks include acute renal failure, severe electrolyte imbalances (especially hyponatremia or hyperkalemia), pulmonary edema from fluid overload, anaphylactic reactions, cardiac arrhythmias, and rapid shifts in intracranial or intraocular pressure that could precipitate hemorrhage.

Mannitol is contraindicated in patients with established anuria, severe renal impairment, active intracranial bleeding, uncontrolled heart failure, severe electrolyte disturbances, and known hypersensitivity to the product. Caution is also advised in pregnant or lactating women and in patients at risk of fluid overload.